A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms
University of Chicago
University of Chicago
Baptist Health South Florida
Medigene AG
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
National Institutes of Health Clinical Center (CC)
Emory University
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota